Cascade secures ~¥500M series round to advance R&D in nuclear receptors and GPCRs

On February 10, Cascade Pharmaceuticals announced that it has recently completed a new round of financing totaling approximately 500 million. This round was led by Zhongping Capital, with joint participation from several prominent investment institutions including China Life Investment, CTS Capital, and Qingdao Conson Capital. Previous lead investor SSCILF, as well as existing shareholders Gaorong Ventures and Bayland Capital, continued to invest additionally.

This financing not only set a new record for Cascade in terms of single-round funding, but also highlighted the capital market's recognition of the R&D team's "strong technical expertise and differentiated pipeline" in the fields of nuclear receptors and GPCR.

The funds raised will be primarily allocated to two key areas: first, accelerating the global multi-center Phase III clinical trial of the lead pipeline and advancing its global registration for indications such as metabolic dysfunction-associated steatohepatitis (MASH), primary biliary cholangitis (PBC), and obesity; second, continuously expanding the R&D pipeline matrix to develop a series of potential best-in-class/first-in-class therapies in the field of metabolic diseases, thereby creating high-quality Chinese solutions.